Dr. Daniels serves as a team leader for the clinical outcome assessments (COA) staff at the U.S. Food and Drug Administration (FDA). She leads a team of expert analysts who evaluate a variety of complex COA endpoint issues related to the evaluation of clinical benefit in registration trials to support labeling claims.
Prior to the FDA, Dr. Daniels was a senior manager in the Global Health Economic and Outcomes Research (HEOR) group at Allergan, where she developed and executed HEOR strategies, as well as developed and implemented innovative COA strategies and endpoints for clinical trials.
